-
Something wrong with this record ?
Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)
M. Rizzo, A. Colletti, PE. Penson, N. Katsiki, DP. Mikhailidis, PP. Toth, I. Gouni-Berthold, J. Mancini, D. Marais, P. Moriarty, M. Ruscica, A. Sahebkar, D. Vinereanu, AFG. Cicero, M. Banach, International Lipid Expert Panel (ILEP)
Language English Country Netherlands
Document type Journal Article, Review
- MeSH
- Diabetes Mellitus, Type 2 * complications MeSH
- Child MeSH
- Adult MeSH
- Liver Cirrhosis complications MeSH
- Cardiovascular Diseases * prevention & control MeSH
- Humans MeSH
- Lipids therapeutic use MeSH
- Non-alcoholic Fatty Liver Disease * drug therapy MeSH
- Dietary Supplements MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Non-Alcoholic Fatty Liver Disease (NAFLD) is a common condition affecting around 10-25% of the general adult population, 15% of children, and even > 50% of individuals who have type 2 diabetes mellitus. It is a major cause of liver-related morbidity, and cardiovascular (CV) mortality is a common cause of death. In addition to being the initial step of irreversible alterations of the liver parenchyma causing cirrhosis, about 1/6 of those who develop NASH are at risk also developing CV disease (CVD). More recently the acronym MAFLD (Metabolic Associated Fatty Liver Disease) has been preferred by many European and US specialists, providing a clearer message on the metabolic etiology of the disease. The suggestions for the management of NAFLD are like those recommended by guidelines for CVD prevention. In this context, the general approach is to prescribe physical activity and dietary changes the effect weight loss. Lifestyle change in the NAFLD patient has been supplemented in some by the use of nutraceuticals, but the evidence based for these remains uncertain. The aim of this Position Paper was to summarize the clinical evidence relating to the effect of nutraceuticals on NAFLD-related parameters. Our reading of the data is that whilst many nutraceuticals have been studied in relation to NAFLD, none have sufficient evidence to recommend their routine use; robust trials are required to appropriately address efficacy and safety.
Cardiovascular Research Centre University of Zielona Gora Zielona Gora Poland
Department of Endocrinology Diabetes and Preventive Medicine University of Cologne Germany
Department of Pharmacological and Biomolecular Sciences University of Milan Milan Italy
Department of Preventive Cardiology and Lipidology Medical University of Lodz Poland
Department of Science and Drug Technology University of Turin Turin Italy
IRCCS Policlinico S Orsola Malpighi Bologna Italy
Liverpool Centre for Cardiovascular Science Liverpool UK
Polish Mother's Memorial Hospital Research Institute Lodz Poland
Preventive Cardiology CGH Medical Center Sterling IL USA
School of Medicine European University Cyprus Nicosia Cyprus
School of Pharmacy and Biomolecular Sciences Liverpool John Moores University Liverpool UK
The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Baltimore MD USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23003926
- 003
- CZ-PrNML
- 005
- 20230425140959.0
- 007
- ta
- 008
- 230418s2023 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.phrs.2023.106679 $2 doi
- 035 __
- $a (PubMed)36764041
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Rizzo, Manfredi $u Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Via del Vespro 141, 90127 Palermo, Italy. Electronic address: manfredi.rizzo@unipa.it
- 245 10
- $a Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP) / $c M. Rizzo, A. Colletti, PE. Penson, N. Katsiki, DP. Mikhailidis, PP. Toth, I. Gouni-Berthold, J. Mancini, D. Marais, P. Moriarty, M. Ruscica, A. Sahebkar, D. Vinereanu, AFG. Cicero, M. Banach, International Lipid Expert Panel (ILEP)
- 520 9_
- $a Non-Alcoholic Fatty Liver Disease (NAFLD) is a common condition affecting around 10-25% of the general adult population, 15% of children, and even > 50% of individuals who have type 2 diabetes mellitus. It is a major cause of liver-related morbidity, and cardiovascular (CV) mortality is a common cause of death. In addition to being the initial step of irreversible alterations of the liver parenchyma causing cirrhosis, about 1/6 of those who develop NASH are at risk also developing CV disease (CVD). More recently the acronym MAFLD (Metabolic Associated Fatty Liver Disease) has been preferred by many European and US specialists, providing a clearer message on the metabolic etiology of the disease. The suggestions for the management of NAFLD are like those recommended by guidelines for CVD prevention. In this context, the general approach is to prescribe physical activity and dietary changes the effect weight loss. Lifestyle change in the NAFLD patient has been supplemented in some by the use of nutraceuticals, but the evidence based for these remains uncertain. The aim of this Position Paper was to summarize the clinical evidence relating to the effect of nutraceuticals on NAFLD-related parameters. Our reading of the data is that whilst many nutraceuticals have been studied in relation to NAFLD, none have sufficient evidence to recommend their routine use; robust trials are required to appropriately address efficacy and safety.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nealkoholová steatóza jater $x farmakoterapie $7 D065626
- 650 12
- $a diabetes mellitus 2. typu $x komplikace $7 D003924
- 650 _2
- $a potravní doplňky $7 D019587
- 650 _2
- $a jaterní cirhóza $x komplikace $7 D008103
- 650 12
- $a kardiovaskulární nemoci $x prevence a kontrola $7 D002318
- 650 _2
- $a lipidy $x terapeutické užití $7 D008055
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Colletti, Alessandro $u Department of Science and Drug Technology, University of Turin, Turin, Italy
- 700 1_
- $a Penson, Peter E $u School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK; Liverpool Centre for Cardiovascular Science, Liverpool, UK
- 700 1_
- $a Katsiki, Niki $u Department of Nutritional Sciences and Dietetics, International Hellenic University, Thessaloniki, Greece; School of Medicine, European University Cyprus, Nicosia, Cyprus
- 700 1_
- $a Mikhailidis, Dimitri P $u Department of Clinical Biochemistry, Royal Free Campus, Medical School, University College London (UCL), London, UK
- 700 1_
- $a Toth, Peter P $u The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA; Preventive Cardiology, CGH Medical Center, Sterling, IL, USA
- 700 1_
- $a Gouni-Berthold, Ioanna $u Department of Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Germany
- 700 1_
- $a Mancini, John $u Department of Medicine, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada
- 700 1_
- $a Marais, David $u Chemical Pathology Division of the Department of Pathology, University of Cape Town Health Science Faculty, Cape Town, South Africa
- 700 1_
- $a Moriarty, Patrick $u Division of Clinical Pharmacology, Division of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
- 700 1_
- $a Ruscica, Massimiliano $u Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
- 700 1_
- $a Sahebkar, Amirhossein $u Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
- 700 1_
- $a Vinereanu, Dragos $u Cardiology Department, University and Emergency Hospital, Bucharest, Romania, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
- 700 1_
- $a Cicero, Arrigo Francesco Giuseppe $u Hypertension and Cardiovascular disease risk research center, Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy; IRCCS Policlinico S. Orsola-Malpighi, Bologna, Italy
- 700 1_
- $a Banach, Maciej $u Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Poland; Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland. Electronic address: maciej.banach@umed.lodz.pl
- 710 2_
- $a International Lipid Expert Panel (ILEP)
- 773 0_
- $w MED00005744 $t Pharmacological research $x 1096-1186 $g Roč. 189, č. - (2023), s. 106679
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36764041 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425140955 $b ABA008
- 999 __
- $a ok $b bmc $g 1924532 $s 1190135
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 189 $c - $d 106679 $e 20230208 $i 1096-1186 $m Pharmacological research $n Pharmacol Res $x MED00005744
- LZP __
- $a Pubmed-20230418
